×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CELC – celcuity inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CELC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/5
09:38 pm
celc
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally [Yahoo! Finance]
Low
Report
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally [Yahoo! Finance]
3/26
08:37 pm
celc
Why Celcuity Stock Popped Today [Yahoo! Finance]
Medium
Report
Why Celcuity Stock Popped Today [Yahoo! Finance]
3/26
11:28 am
celc
Celcuity (CELC) had its price target raised by Stifel Nicolaus from $115.00 to $125.00. They now have a "buy" rating on the stock.
Low
Report
Celcuity (CELC) had its price target raised by Stifel Nicolaus from $115.00 to $125.00. They now have a "buy" rating on the stock.
3/26
08:42 am
celc
Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
Medium
Report
Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
3/25
11:23 pm
celc
Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... [Yahoo! Finance]
Medium
Report
Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... [Yahoo! Finance]
3/25
08:20 pm
celc
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/25
08:18 pm
celc
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations [Seeking Alpha]
Medium
Report
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations [Seeking Alpha]
3/25
06:22 pm
celc
Celcuity Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Celcuity Q4 Earnings Call Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
04:03 pm
celc
Form 4 Celcuity Inc. For: Apr 09 Filed by: NIGON RICHARD
Low
Report
Form 4 Celcuity Inc. For: Apr 09 Filed by: NIGON RICHARD
4/2
04:41 pm
celc
Form ARS Celcuity Inc. For: Dec 31
Low
Report
Form ARS Celcuity Inc. For: Dec 31
4/2
04:31 pm
celc
Form DEF 14A Celcuity Inc. For: Apr 02
Low
Report
Form DEF 14A Celcuity Inc. For: Apr 02
4/2
04:06 pm
celc
Form 4 Celcuity Inc. For: Mar 31 Filed by: Buller Richard E
Low
Report
Form 4 Celcuity Inc. For: Mar 31 Filed by: Buller Richard E
3/31
04:39 pm
celc
Form 144 Celcuity Inc. Filed by: Buller Richard E
Low
Report
Form 144 Celcuity Inc. Filed by: Buller Richard E
3/26
07:31 am
celc
Form 10-K Celcuity Inc. For: Dec 31
Medium
Report
Form 10-K Celcuity Inc. For: Dec 31
3/25
04:10 pm
celc
Form 8-K Celcuity Inc. For: Mar 25
Medium
Report
Form 8-K Celcuity Inc. For: Mar 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
7.9%
4/23 Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call 7.6%
5/8 Celcuity Inc (NASDAQ: CELC) was given a new $36.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 3.2%
7/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 2.8%
5/20 Celcuity Announces Appointment of Leo Furcht to Board of Directors 2.1%
11/7 Q3/2019 9/30/2019 EPS -0.160 ZacksConsensus -0.180 ActVsEst 0.020 - Beat 1.9%
8/8 Celcuity Reports Second Quarter 2019 Financial Results 1.6%
1/13 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.5%
2/24 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.5%
5/20 Form 4 Celcuity Inc. For: May 16 Filed by: NIGON RICHARD 1.4%
4/23 Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call 7.6%
5/8 Celcuity Inc (NASDAQ: CELC) was given a new $36.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 3.2%
7/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 2.8%
5/20 Celcuity Announces Appointment of Leo Furcht to Board of Directors 2.1%
11/7 Q3/2019 9/30/2019 EPS -0.160 ZacksConsensus -0.180 ActVsEst 0.020 - Beat 1.9%
8/8 Celcuity Reports Second Quarter 2019 Financial Results 1.6%
1/13 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.5%
2/24 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.5%
5/20 Form 4 Celcuity Inc. For: May 16 Filed by: NIGON RICHARD 1.4%
TOP News Decliners
2/14
Form SC 13G/A Celcuity Inc. Filed by: Sullivan Brian F.
-5.1%
8/1 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock. -4.3%
3/13 Celcuity Inc (NASDAQ: CELC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, down previously from $36.00. -3.6%
10/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -3.3%
8/10 Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -1.9%
11/20 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -1.1%
7/25 Celcuity Inc. Schedules Release of Second Quarter 2019 Financial Results and Conference Call -1.1%
12/11 Celcuity Presents Results at the 2019 San Antonio Breast Cancer Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K Inhibitors -0.9%
11/11 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/27 Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2019 Financial Results and Conference Call -0.7%
8/1 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock. -4.3%
3/13 Celcuity Inc (NASDAQ: CELC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, down previously from $36.00. -3.6%
10/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -3.3%
8/10 Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -1.9%
11/20 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -1.1%
7/25 Celcuity Inc. Schedules Release of Second Quarter 2019 Financial Results and Conference Call -1.1%
12/11 Celcuity Presents Results at the 2019 San Antonio Breast Cancer Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K Inhibitors -0.9%
11/11 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/27 Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2019 Financial Results and Conference Call -0.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: